1By the French Adjuvant Group.Benefit of a high-dose epirubicin regimen in adjuvant chemotherapy for node-positive breast cancer patients with poor prognostic factors: 5-year results of french adjuvant study group 05 randomised trial[].Journal of Clinical Oncology.2001
2Peters W,Rosner G,Vredenburgh J,et al.A prospective randomised comparision of two doses of combination alkylating agents as consolidation after CAF in high risk primary breast cancer involving ten or more axillary lymph nodes: preliminary results of CALGB 9082/SWOG 9114/NCIC13[].Proceedings of the American Society of Clinical Oncology.1999
3By the French Epirubicin Study Group.Epirubicin-based chemotherapy in metastatic breast cancer patients: role of dose-intensity and duration of treatment[].Journal of Clinical Oncology.2000
4Stadtmauer EA,O′Neill A,Goldstein LJ,et al.Conventional-dose chemotherapy compared with high-dose chemotherapy plus autologous hematopoietic stem-cell transplantation for metastatic breast cancer[].The New England Journal of Medicine.2000
5Hudis C,Seidman A,Baselga SJ,et al.Sequential dose-dense doxorubicin, paclitaxel, and cyclophosphamide for resectable high-risk breast cancer: feasibility and efficacy[].Journal of Clinical Oncology.1999
6Fountzilas G,Papadimitriou C,Aravantinos G,et al.Dose-dense sequential adjuvant chemotherapy with epirubicin, paclitaxel and CMF in high-risk breast cancer[].Oncology.2001
7Lotz J P,Cure H,Janvier M,et al.High-dose chemotherapy (HD-CT)with hmatopoietic stem cells transplantation (HSCT) for metastatic breast cancer (MBC): results of the French Protocol PEGASE 04[].Proceedings of the American Society of Clinical Oncology.1999
8Hortobagyi GN,Buzdar AU,Theriault RL,et al.Randomized trial of high-dose chemotherapy and blood cell autografts for high-risk primary breast carcinoma[].Journal of the National Cancer Institute.2000
9Bezwoda WR.Randomised controlled trial of high dose chemotherapy(HD-CNVp) versus standard CAF chemotherapy for high-risk, surgically treated, primary breast cancer[].Proceedings of the American Society of Clinical Oncology.1999
